Loading
A phase 2 trial of Contrast-enhanced mammography in Breast cancer, run by European Institute of Oncology, with a status the registry has not verified recently.
Contrast-Enhanced Spectral Mammography (CESM) is a phase 2 interventional study registered as NCT06311695 by European Institute of Oncology, with 263 participants planned, started 2020-11-16 and due to reach its primary completion in 2025-02-28. Interventions recorded: Contrast Enhanced Mammography. Conditions recorded: Breast Cancer.
Linked to the technology Contrast-enhanced mammography because the registry names it ("contrast enhanced mammography") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/